Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 172.22 USD -0.42% Market Closed
Market Cap: 10.4B USD

EV/EBIT
Enterprise Value to EBIT

-27.2
Current
-12.1
Median
4.5
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-27.2
=
Enterprise Value
10.4B USD
/
EBIT
-326.3m EUR
EBIT Growth EV/EBIT to Growth
DK
Ascendis Pharma A/S
NASDAQ:ASND
Average EV/EBIT: 19.5
Negative Multiple: -27.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 630.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
21.9
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.6
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.9
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.4 N/A N/A
AU
CSL Ltd
ASX:CSL
20.9
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -350.7 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-37
2-Years Forward
EV/EBIT
79
3-Years Forward
EV/EBIT
17.1